Researchers developed and validated a new lung cancer prediction model, Sybil-Epi, by integrating clinical and epidemiologic data with a pre-existing model.
Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, ...
CLAIRITY BREAST provides clinicians with a first-in-class, novel platform for identifying future risk of breast cancer CLAIRITY BREAST analyzes subtle imaging features on screening mammograms that ...
Re-prompting for ESR1 mutations in breast cancer: Improving mutation reporting and therapeutic decision-making. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This ...
The intersection of artificial intelligence (AI) and healthcare presents a transformative frontier, particularly in the global fight against cancer. As healthcare systems worldwide grapple with rising ...
Low-dose computed tomography (LDCT) screening is effective in reducing lung cancer mortality by detecting the disease at earlier, more treatable stages. However, high false-positive rates and the ...
New AI-driven systems for detecting and predicting gastrointestinal cancers have been developed through research projects in Singapore and South Korea. A research team from Singapore General Hospital ...
Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S. Food and Drug Administration (FDA) De Novo authorization for CLAIRITY BREAST, a novel, ...
A machine learning model that analyzes patient demographics, electronic health record data, and routine blood test results predicted a patient's risk of hepatocellular carcinoma (HCC), the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results